Analyst Scoreboard: 6 Ratings For AbbVie
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for AbbVie (NYSE:ABBV) over the past three months, with a majority being somewhat bullish. The average 12-month price target is $189.5, slightly down from the previous $190.75. Key financial indicators show strong profitability and financial performance, but high debt levels.
June 05, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed ratings for AbbVie, with a majority being somewhat bullish. The average 12-month price target is $189.5, slightly down from the previous $190.75. Key financial indicators show strong profitability and financial performance, but high debt levels.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on AbbVie's stock price. While the company's financial indicators are strong, the high debt levels could be a concern for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100